TTTakeshi Terazawa

Takeshi Terazawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takeshi Terazawa has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of a Transfer Learning-Based Interactive Tool for Pathological Image Tissue Segmentation

    by Takeshi Terazawa, Hoshiro Sato, Toshiya Arakawa

    病理画像の組織種セグメンテーションは,高度な専門知識と多大な労力を要する.本研究では,作業者のアノテーション情報を逐次学習し,予測結果を修正することで精度向上を図る対話型セグメンテーションツールを開発した.本ツールはランダムフォレストを用いマッソン・トリクローム染色画像を「細胞核」,「コラーゲン」,「背景」に識別する.ツールの有効性評価のため,専門家よりトレーニングを受けた評価者1名が実験を実施し,IoUとアノテーション操作回数で評価した.その結果,ツールは手作業と同等の精度を維持しつつ作業効率を約1/10に改善した.転移学習による新規画像への適用を試みたところ,明確な効率改善効果は得られなかったが,細胞核認識精度の課題が示唆された.形状特徴量の追加により精度と効率改善が期待される.

  • Open Access

    Acute Phase Pilot Evaluation of Small Diameter Long iBTA Induced Vascular Graft “Biotube” in a Goat Model

    by Ryuji Higashita, Yasuhide Nakayama, Yasuyuki Shiraishi, Ryosuke Iwai, Yusuke Inoue, Akihiro Yamada, Takeshi Terazawa, Tsutomu Tajikawa, Manami Miyazaki, Mamiko Ohara, et al.


  • Open Access

    iBTA-Induced Biotube® Blood Vessels: 2020 Update

    by Yasuhide Nakayama, Ryuji Higashita, Yasuyuki Shiraishi, Tadashi Umeno, Tsutomu Tajikawa, Akihiro Yamada, Kazuki Mori, Manami Miyazaki, Mamiko Ohara, Ryosuke Iwai, et al.

    Blood access is a lifeline for dialysis patients. However, serious problems such as stenosis or obstruction of access blood vessels, which are life-threatening conditions in daily clinical practice, still remain. One of the most promising candidates for solving these problems may be Biotube blood vessels. More than 20 years have passed since the development of in-body tissue architecture (iBTA), a technology for preparing tissues for autologous implantation in patients. The tissues obtained by iBTA do not elicit immunological rejection, which is one of the ultimate goals of regenerative medical engineering; however, their practical applications were quite challenging. The seemingly unorthodox iBTA concepts that do not follow the current pre-established medical system may not be readily accepted in general medicine. In contrast, there are many diseases that cannot be adequately addressed even with the latest and most advanced medical technology. However, iBTA may be able to save patients with serious diseases. It is natural that the development of high-risk medical devices that do not fit the corporate logic would be avoided. In order to actively treat such largely unattached diseases, we started Biotube Co., Ltd. with an aim to contribute to society. Biotubes induced by iBTA are collagenous tubular tissues prepared in the patient’s body for autologous implantation. The application of Biotubes as tissues for vascular implantation has been studied for many years. Biotubes may have excellent potential as small-diameter artificial blood vessels, one of the most difficult to clinically achieve. Their possibility is currently being confirmed in preclinical tests. Biotubes may save hundreds of thousands of patients worldwide annually from amputation. In addition, we aim to eliminate the recuring access vascular problems in millions of dialysis patients. This study provides an update on the current development status and future possibilities of Biotubes and their preparation molds, Biotube Makers.